Showing posts with label journal of prostate cancer. Show all posts
Showing posts with label journal of prostate cancer. Show all posts

Wednesday, 26 July 2017

Stereotactic Radiotherapy for Localized Prostate Cancer, which is Better CyberKnife or RapidArc?

Stereotactic Radiotherapy
We aim to compare two different stereotactic body radiation therapy (SBRT) techniques, non-isocentric CyberKnife (CK) with isocentric RapidArc (RA), more widely available treatment technique for the treatment of localized prostate cancer.
The study included six patients treated with CK then re-planned with the new version of flattening filter free (FFF) RA and CK. The prescription dose was 36.25 Gy in five fractions. The two SBRT techniques were compared by target coverage, normal tissue sparing, dose distribution parameters and delivery time.
The RA technique exhibited comparable PTV coverage and better bladder and rectum sparing at high doses. The conformity and homogeneity indices of the RA were better and statistically significant than the CK plans.

Tuesday, 30 May 2017

Robotic Radical Prostatectomy and Nerve Grafting: Does it Actually Work?

radical prostatectomy
Robotic radical prostatectomy is now the gold standard for patients with localised prostate cancer. In the setting of unfavourable prostate pathology, some men may require resection of one or both cavernous nerves at the time of prostatectomy.

Potency rates in this subset of men are expectedly dismal. With increasing numbers of younger men being diagnosed with prostate cancer and subsequently undergoing radical prostatectomy, there is an increasing focus on quality of life postoperatively, especially potency.

Nerve-grafting surgery after resection of neuro-vascular bundles during radical prostatectomy is one of the promising resolutions for dilemma between cancer control and functional preservation.

Monday, 3 April 2017

Should Centralized Histopathological Review in Prostate Cancer be the Gold Standard?

Histopathological Review in Prostate Cancer
To assess the potential impact of centralized histopathological review on prostate cancer management. Methods: 1) Biopsy slides of 277 men with newly diagnosed prostate cancer between January 2010 and March 2014 from 22 centers were referred to our tertiary referral center for centralized histopathological review.

The biopsy Gleason score and D’Amico prognostic risk group were compared between those of the referring pathologists and those after assessment by a centralized histopathological review committee consisting of two specialized uro-pathologists.

Alterations in biopsy Gleason score and D’Amico prognostic risk group between referring pathologists and centralized histopathological committee were subdivided into treatment changes (i.e., lymph-node dissection, nerve sparing surgery, or active surveillance) and diagnostic changes (bone scintigraphy).

Thursday, 5 January 2017

Should Centralized Histopathological Review in Prostate Cancer be the Gold Standard?

To assess the potential impact of centralized histopathological review on prostate cancer management. Methods: Biopsy slides of 277 men with newly diagnosed prostate cancer between January 2010 and March 2014 from 22 centers were referred to our tertiary referral center for centralized histopathological review.

prostate cancer
The biopsy Gleason score and D’Amico prognostic risk group were compared between those of the referring pathologists and those after assessment by a centralized histopathological review committee consisting of two specialized uro-pathologists.

Alterations in biopsy Gleason score and D’Amico prognostic risk group between referring pathologists and centralized histopathological committee were subdivided into treatment changes (i.e., lymph-node dissection, nerve sparing surgery, or active surveillance) and diagnostic changes (bone scintigraphy).

Wednesday, 28 December 2016

Quality of Life and Sexual Activity after Stereotactic Hypofractionated Radiotherapy of Prostate Cancer Patients

Quality of life (QoL) is an important factor for the cancer patients after treatment. The study aimed to investigate QoL and sexual activity in patients who had undergone stereotactic hypofractionated radiotherapy (HRT). Methods: The analysis included 82 prostate cancer patients: 40 patients treated by HRT (33.5 Gy in 5 fractions) and 42 patients treated by standard three-dimensional conformal radiation treatment 3DCRT (70-82 Gy in 35-41 fractions); and 50 healthy men without any type of cancer.

Radiotherapy of Prostate Cancer Patients
The subjects filled out the questionnaires: EORTC QLQC30 (version 3.0.) and the prostate cancer-specific EORTC QLQ-PR25. The median follow-up was 21 months for HRT patients and 28 months for 3DCRT patients. Results: The tolerance for stereotactic HRT was shown to be good. The QoL and the general health status of HRT patients were higher than of 3DCRT patients and even of healthy men. Most patients treated by HRT felt that they had lost their masculinity.

However, they were still interested in having sex; one third of them were sexually active, most reported satisfaction with their sex life. Conclusions: HRT for prostate cancer patients was an attractive treatment in relation to patients' QoL assessment in the short term analysis.


Friday, 25 November 2016

Robotic Radical Prostatectomy and Nerve Grafting: Does it Actually Work?

Robotic radical prostatectomy is now the gold standard for patients with localised prostate cancer. In the setting of unfavourable prostate pathology, some men may require resection of one or both cavernous nerves at the time of prostatectomy. Potency rates in this subset of men are expectedly dismal.

Robotic Radical Prostatectomy
With increasing numbers of younger men being diagnosed with prostate cancer and subsequently undergoing radical prostatectomy, there is an increasing focus on quality of life postoperatively, especially potency. Nerve-grafting surgery after resection of neuro-vascular bundles during radical prostatectomy is one of the promising resolutions for dilemma between cancer control and functional preservation.

There have been a number of articles recently on nerve grafting for robotic radical prostatectomy. We aim to review the evidence for whether this actually works and gives a good degree of erectile function.

Monday, 17 October 2016

Quality of Life and Sexual Activity after Stereotactic Hypofractionated Radiotherapy of Prostate Cancer Patients

Prostate cancer is the most prevalent solid tumor diagnosed in men in developed countries. The standard treatment for early stage prostate cancer is surgery (prostatectomy) or radiotherapy. To improve local control, the radiation dose should be escalated. Threedimensional conformal radiation treatment (3DCRT) increases local control rates while decreasing toxicity rates.

Prostate Cancer Patients
Recent data suggest that, to achieve high local control of prostate cancer with acceptable toxicity, hypofractionated radiotherapy (HRT) could be used. Short-duration HRT is an attractive option compared with a 7-to-8-week course of standard radiotherapy in terms of logistics the patient’s job, daily activities, and emotions; the availability of accelerators, and the cost of prolonged treatment.

Quality of life (QoL) has become one of the most significant issues in treatment decisions in prostate cancer. In the case of QoL measurement after radical prostatectomy, brachytherapy, or external beam radiotherapy, all types of prostate cancer treatment were shown to be associated with changes in the QoL domains related to urinary, bowel, and sexual functions.

Thursday, 13 October 2016

Eradicating Health Care Disparities in the Surgical Management of Prostate Cancer

Racial disparities in prostate cancer epidemiology and survival outcomes generally have been well documented, with assorted facts and figures indicating that African-American men are disadvantaged with regard to disease control and therapeutic gains associated with this disease relative to their Caucasian-American counterparts.

Prostate Cancer
Prostate cancer is a daunting disease state for all Americans: it represents the most commonly diagnosed malignancy and the second most common cause of cancer-related deaths in the United States. However, for African-American men, the public health implications of this disease are all the more sobering: the disease incidence is 1.62-fold greater for African-American men than for Caucasian-American men and the mortality rate-ratio is 2.45-fold greater, respectively.

In blunt absolute terms, 1 in 3 African-American men will be at risk for developing clinically significant prostate cancer and as much as 1 in 5 African-American men >50 years of age will die of this disease.

Tuesday, 4 October 2016

Eradicating Health Care Disparities in the Surgical Management of Prostate Cancer

Racial disparities in prostate cancer epidemiology and survival outcomes generally have been well documented, with assorted facts and figures indicating that African-American men are disadvantaged with regard to disease control and therapeutic gains associated with this disease relative to their Caucasian-American counterparts.

Prostate Cancer
Prostate cancer is a daunting disease state for all Americans it represents the most commonly diagnosed malignancy and the second most common cause of cancer-related deaths in the United States. However, for African-American men, the public health implications of this disease are all the more sobering: the disease incidence is 1.62-fold greater for African-American men than for Caucasian-American men and the mortality rate-ratio is 2.45-fold greater, respectively.

In blunt absolute terms, 1 in 3 African-American men will be at risk for developing clinically significant prostate cancer and as much as 1 in 5 African-American men >50 years of age will die of this disease.

Monday, 26 September 2016

Life and Sexual Activity

Prostate cancer is the most prevalent solid tumor diagnosed in men in developed countries. The standard treatment for early stage prostate cancer is surgery (prostatectomy) or radiotherapy. To improve local control, the radiation dose should be escalated.

Hypofractionated Radiotherapy of Prostate
Three dimensional conformal radiation treatment (3DCRT) increases local control rates while decreasing toxicity rates. Recent data suggest that, to achieve high local control of prostate cancer with acceptable toxicity, hypofractionated radiotherapy (HRT) could be used. Short-duration HRT  is an attractive option compared with a 7-to-8-week course of standard radiotherapy in terms of logistics; the patient’s job, daily activities, and emotions; the availability of accelerators, and the cost of prolonged treatment.

Quality of life (QoL) has become one of the most significant issues in treatment decisions in prostate cancer. In the case of QoL measurement after radical prostatectomy, brachytherapy, or external beam radiotherapy, all types of prostate cancer treatment were shown to be associated with changes in the QoL domains related to urinary, bowel, and sexual functions.